Chicago Cubs spotlight men's health for Father's Day
This Father's Day, the Chicago Cubs are reminding dads that when it comes to things health-related, sometimes it's not enough just to rub some dirt on it.
The Cubs teamed up Sunday with Advocate Health Care to spotlight men's health. They hosted a Father's Day brunch for Advocate patients.
Among those in attendance was 67-year-old prostate cancer survivor Clark Atwater.
Atwater lost his own father to prostate cancer years ago. But he was still shocked when he himself got the diagnosis.
"I didn't really have any symptoms, so a week before my yearly checkup, and gosh, here I am with a PSA elevated," Atwater said. "It's very important to get checked. Get your annual physicals, and ask for your PSA."
Atwater is now in remission and feeling good. In fact, he is feeling so good that he threw out the ceremonial first pitch at Wrigley Field on Sunday, with his grandson by his side.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson's Disease
- Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson's disease - - Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson's disease progression - - Parkinson's disease affects over 10 million people globally and significant unmet need remains - SOUTH SAN FRANCISCO, Calif., June 16, 2025--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein antibody, in early-stage Parkinson's disease. This decision is informed by data from the Phase IIb PADOVA study and ongoing open-label extensions (OLEs) of PADOVA and Phase II PASADENA studies. "We are encouraged by the efficacy signals observed across the two Phase II trials and their open-label extensions, combined with the favorable safety and tolerability profile of prasinezumab," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. "We also recognize the substantial need for new treatment options, and the totality of data suggest that prasinezumab may have the potential to become the first disease-modifying treatment for people with Parkinson's disease." Multiple endpoints from the PADOVA and OLE studies suggest a potential clinical benefit of prasinezumab when added to effective symptomatic treatment in early-stage Parkinson's disease. Prasinezumab showed potential clinical efficacy in the primary endpoint of time to confirmed motor progression, although missed statistical significance. Positive trends towards reduced motor progression at 104 weeks (two years) were observed; these effects appear to be sustained over longer treatment periods based on additional OLE data. The PADOVA study also provided the first biomarker evidence of prasinezumab impacting the underlying disease biology. The PASADENA and PADOVA OLE studies, which are evaluating the long-term safety and efficacy of prasinezumab in over 750 people with early-stage Parkinson's disease, are ongoing. About prasinezumab Prasinezumab is an investigational monoclonal antibody designed to bind aggregated alpha-synuclein and thereby reduce neuronal toxicity. By reducing the build-up of alpha-synuclein protein in the brain, prasinezumab can potentially prevent further accumulation and spreading between cells, which may slow progression of the disease. Data from the Phase IIb PADOVA study suggest the possible clinical benefit of prasinezumab on top of effective symptomatic treatment in early-stage Parkinson's disease. PADOVA investigated prasinezumab in 586 people with early-stage Parkinson's disease, treated for a minimum of 18 months while on stable symptomatic treatment. Prasinezumab showed potential clinical efficacy in the primary endpoint of time to confirmed motor progression with a HR=0.84 [0.69-1.01], although the study missed statistical significance (p=0.0657). In a pre-specified analysis, the effect of prasinezumab was more pronounced in the population treated with levodopa (75% of participants), HR=0.79 [0.63-0.99], p=0.0431 (nominal). Consistent positive trends across multiple secondary and exploratory endpoints were also observed. Trends towards reduced motor progression at 104 weeks (two years) were observed, showing 30-40% relative reduction versus placebo across the overall and levodopa-treated populations. Prasinezumab continues to be well tolerated and no new safety signals were observed in the study. The safety database for prasinezumab consists of data from more than 900 Parkinson's disease study participants that have been treated with the investigational medicine, of which more than 750 remain in open label treatment with over 500 treated for 1.5-5 years. Roche/Genentech entered into a Licensing, Development, and Commercialization agreement with Prothena in December 2013 to develop and commercialize monoclonal antibodies targeting aggregated alpha-synuclein, such as prasinezumab, for the treatment of Parkinson's disease. About Parkinson's disease Parkinson's disease is a chronic, progressive and debilitating neurodegenerative disease characterized by the gradual loss of neurons that make dopamine and other nerve cells, and the development of motor and non-motor symptoms that may appear years before diagnosis. Today, Parkinson's disease affects over 10 million people worldwide. The prevalence of Parkinson's disease is increasing, and it has become one of the fastest-growing neurological disorders. Currently, symptomatic treatments that effectively alleviate motor symptoms are available today, having a significant impact on people's quality of life; however, no available symptomatic therapies slow down or stop the clinical progression of Parkinson's disease and the effects wear off over time as the disease progresses. Genentech and Roche are evaluating multiple approaches to slow down disease progression and potentially prevent Parkinson's disease that involve targeting underlying disease processes such as aggregated α-syn production, lysosomal dysfunction and neuroinflammation. About Genentech in Neuroscience Neuroscience is a major focus of research and development at Genentech. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases. Genentech and Roche are investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer's disease, Huntington's disease, Parkinson's disease and Duchenne muscular dystrophy. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today. About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit View source version on Contacts Media Contact:Meghan Hindman (650) 467-6800 Advocacy Contact:Jenee Williams (650) 303-2958 Investor Contacts:Loren Kalm (650) 225-3217Bruno Eschli +41 61 687 5284 Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
33 Brutally Honest Confessions From An ER Doctor That Changed The Way I Think About The Hospital
Recently, on Reddit, an emergency room doctor hosted an AMA, inviting users to "ask me anything" about their profession. They started the thread by writing, "Hi Reddit, I'm an ER doctor with 5 years of experience working at a busy community trauma center. I've seen a wide spectrum of human experience come through those doors—car crashes, gunshot wounds, overdoses, and the truly bizarre. Some nights it's nonstop controlled chaos; other times it's quiet until it suddenly isn't. Ask me anything about what really happens behind the scenes—wild cases, ethical gray areas, tough conversations, dealing with patients who don't want help, etc. I'll answer as openly and honestly as I can, while respecting privacy and patient confidentiality. Let's talk." Here are some of the best questions and answers from the AMA: 1.Q: What led you to become an ER doctor, and what part of your job could drive you away from wanting to continue to be one? A: I was drawn to emergency medicine because I loved the variety, every rotation in med school had me thinking, "I want to do this," and the ER let me do a bit of everything. I also really like the shift work. When my shift ends, I'm done. A full-time schedule is around 120 hours a month, so most days I still get to enjoy life outside the hospital. I don't really know what would make me leave. A lot of ER docs do burn out eventually, but so far, I still really love it. 2.Q: How much money do you make? A: Right now, I make around $500K a year before taxes. It depends a lot on location, schedule, and whether you're doing extra shifts or working in high-volume or underserved areas. Emergency medicine can pay well, but it definitely comes with its own stress and intensity. I have colleagues who make less and others who pulled in over a million last year. 3.Q: What would you keep at home if you really wanted to not die from anything that's sometimes immediately fatal (ie, stroke, pulmonary embolism)? A: If you're thinking about true lifesavers for sudden, potentially fatal events, I always keep Narcan (naloxone) in my car; it's easy to use and can absolutely save a life in an opioid overdose. Beyond that, though, most things like stroke or pulmonary embolism need rapid recognition and emergency care; you can't really stock your way out of those. The best 'kit' is knowing the warning signs and not waiting to call 911. 4.Q: One health tip for the general public given your position and experience? A: If I had to give one health tip based on what I see every day: wear a seatbelt, don't drive drunk, and stay off motorcycles. I've seen too many lives changed — or ended —because of those exact things. Simple choices, but they make a huge difference. 5.Q: I imagine you must have lost a patient at some point. How do you handle informing the family, and how do you make sure it doesn't affect you personally? A: Breaking bad news is something you learn to do over time; it's never easy, but I try to approach it with honesty and compassion. I actually feel lucky to be able to sit with families during those moments and help guide them through it. There are a few things I consider essential when it comes to delivering bad news. First, make sure the entire team is on the same page. It's important that no one gives conflicting or confusing information. Second, I always start by gently finding out what the family already knows or understands, which helps guide the conversation. Then I'm honest and direct. I try not to use vague language. I tell them clearly what happened, give them a moment to process, and then ask if they have any questions. It's also important to reassure them that we did everything we could, and that their loved one was treated with care and dignity, like we would treat our own family. You don't need the perfect words; what people remember most is that you were present, honest, and kind. 6.Q: Recently, a wonderful younger doctor took care of us in the ER, and I would like to give him something to show our appreciation, but I'm not sure what. Any suggestions? Thanks for helping other humans survive! A: Great question! Most of us can't accept personal gifts, but sometimes people bring cookies or snacks for the whole staff, which is a kind gesture, though even that can be a bit delicate depending on hospital policy. Honestly, the best gift is to reach out to the hospital and share your appreciation directly, an email to leadership, a kind note, or even a Google review mentioning their name if allowed. That kind of recognition really does get back to us and means a lot. 7.Q: What's the craziest case you saw? A: One of the craziest cases I've seen was a young patient who had a massive pulmonary embolism (blood clot in the lungs) and was bleeding heavily into her abdomen at the same time. She was literally dying from clotting too much and bleeding too much at once. Treating one made the other worse — it was an incredibly tough balance and a real challenge medically. She had a thrombectomy, then emergency surgery, and was placed on ECMO. Amazingly, she walked out of the hospital a few weeks later. 8.Q: What was the most surreal/bizarre situation you experienced during a shift? A: A psych patient once escaped through the ceiling. Literally climbed up and got into the ductwork. Security had to call the police, and it turned into a full-on manhunt in the hospital. Definitely one of the more surreal nights. 9.Q: Have you seen The Pitt? If so, what does it get right and what does it get wrong? A: Yes, I've seen The Pitt and honestly, it's incredibly accurate when it comes to showing the emotional weight and chaotic pace of emergency medicine. It captures the human side of the job better than any other medical show I've watched. What it gets wrong is the frequency of rare procedures; they stack dramatic, once-in-a-career cases back to back, when in reality, some of those things might only show up every few years. But overall, it's surprisingly true to the experience. 10.Q: How often do you think people in extreme pain, perhaps not from an obvious source, are denied pain medication by doctors suspicious of their claims? A: The only times I hold off on giving pain meds are when someone is so sick that the pain might actually be helping keep them alive, or when we need to address something more urgent first, like stabilizing them or protecting their airway. Otherwise, I take pain seriously, even if the source isn't obvious right away. Just because we can't see it doesn't mean it's not real. Related: 23 Cute, Happy, And Wholesome Posts I Saw On The Internet This Week That You Absolutely Need To See 11.Q: Why do emergency doctors tell you what is wrong with you and to follow up with your doctor for further testing, instead of doing the testing while you're in the hospital? A: Good question. The ER's main job is to rule out emergencies and stabilize people —we're not really set up for full diagnostic workups like MRIs for chronic back pain. Every test we order ties up a bed, delays care for others, and pushes us further behind. That said, if it's a slow shift or someone really struggles with outpatient follow-up, I try to go the extra mile when I can. 12.Q: When people come through and they have health anxiety and they are talking way too much because that's how they cope, does it annoy you? A: Haha, not at all. I've gotten pretty good at gently redirecting the conversation so I can get the info I need while still helping people feel heard. I know health anxiety is real, and if someone's talking a lot, it usually means they're scared. My job is to help them feel safe and supported while making sure nothing serious is going on. 13.Q: What are common issues that are right on the border of needing to go to the ER vs Urgent Care and vice versa? Like, where you say, 'Yeah, I can see why you thought to go to urgent care vs. the ER, but you really should have come to the ER,' and vice versa. A: That's a tough one; there's no perfect line between urgent care and the ER. Minor things like small cuts, sprains, or basic infections are usually fine for urgent care. But anything more serious, like chest pain, trouble breathing, bad abdominal pain, high fevers in neonates, or anything that could be life-threatening, you should head to the ER. 14.Q: Have you ever seen signs of obvious terminal cancer that were a complete surprise to the patient being seen? A: Unfortunately, yes. We see that more often than you'd think. There's a saying in the ER that the nicer the patient, the worse the diagnosis. 15.Q: As someone who gets panic attacks, what do you think when someone shows up with one? A: I'm always happy to help. Panic attacks can feel terrifying and very real, so I never judge anyone for coming in. Part of my job is to make sure it's not something more serious, and then help calm things down from there. If you're scared enough to come to the ER, that means you need care, and that's what we're here for. 16.Q: Your answers have been very empathetic and thoughtful—do you think most of your colleagues have a similar attitude toward patient care, tolerance, etc? A: Thanks. Everyone's a little different, but in general, I do think most people in this line of work, like doctors, nurses, techs, etc., choose it because we genuinely want to help. Related: 40 Really, Really, Really, Really, Really, Really, Really, Really, Really, Really, Really, Really, Really, Really, Really, Really Creepy Wikipedia Pages 17.Q: My 17-year-old just graduated from high school and got through an EMT program in her senior year. She is going to college in the fall, doing pre-med. Her end goal is to be an ER physician. I want my kid to reach her potential, and she is for sure cut out for it, personality-wise, but would you actually recommend the profession to others? If you had a chance to do over and pick a different career (or specialty), would you? A: That's a great question. Being an EMT is an awesome way to get started in medicine. I did it myself and really loved it. It gives you a sense of the pace, pressure, and human side of healthcare early on. As for recommending the profession: yes, if it fits. Emergency medicine is intense, but it can also be incredibly rewarding. The best advice I can give your daughter is to go into med school with an open mind. Every specialty has its own lifestyle, culture, and challenges, and what you think you want going in might not be what grabs you once you're in it. One of the things I love about EM is the schedule. Full-time is about 12 shifts a month, so I have a lot of time to do things I enjoy outside of work. If she's got the personality for it, it can be an amazing fit. But she should explore everything before locking it in. 18.Q: I'm extremely phobic about needles and blood. If I came in in distress, what would your staff be able to do to make things less traumatic for me? I'm really afraid that if I thought I was having a heart attack or something, I would genuinely think twice about going in for help. A: You'd be surprised how many people come in with similar fears. If you ever think you're having a life-threatening emergency, please don't let the fear of needles stop you from coming in. Our job is to help, not to judge. 19.Q: Knowing what you know and having seen what you've seen, what advice would you give us? A: If there's one thing I've learned, it's that family is the most important thing. At the end of someone's life, no one talks about the news, politics, or work. It's all about the people they love — holding hands, saying goodbye, being surrounded by family. Those moments make everything else fade into the background. 20.Q: What is the FUNNIEST thing that has happened? A: One of the funniest things to me is when people get 'cured' in the lobby before they even make it back to a room. My favorite is kids with nasal foreign bodies, like a bead or a piece of food, who suddenly sneeze it out while waiting. Instant fix, everyone's surprised, and half the time the kid acts like nothing even happened. Happens more often than you'd think! 21.Q: Is there any particuliar kind of accidents you prefer not to see? A: Anything involving child abuse. I can handle all the gore — blood, trauma, even death — but when it's clear a child was intentionally hurt by someone, it hits different. That stuff stays with you. 22.Q: Are there days or times of year when the ER is a lot busier? A: Mondays are usually the busiest, and we also see spikes right after big storms or bad weather clears. 23.Q: Does work provide any resources to help you recover from any trauma you experience as a result of being exposed to intense scenarios? A: Yes, we do have access to support resources like counseling and employee assistance programs. But honestly, one of the most helpful things is making sure we debrief as a whole team — nurses, techs, everyone — after especially tough or traumatic cases. 24.Q: What's the funniest story behind an injury you've treated? A: We once had a guy come in with a penile fracture (yep, it's a real thing), and he absolutely refused to say how it happened. Total mystery until his wife walked in wearing 5-inch stilettos and just gave him a look. No one said a word after that, but we all kind of got the picture. 25.Q: Do you enjoy working with paramedics or do they bother you? A: I really enjoy working with paramedics, especially the ones who are engaged and curious, and I always try to follow up with them when I can so they know how their patient did. We're all part of the same team. The only thing that can be a turn-off is when someone's overconfident to the point that they miss something important, like a STEMI, or ignore a patient's pain. There's no room for ego in this work; we all need to stay sharp and humble because lives depend on it. 26.Q: I went to the ER recently for upper GI pain (it was bad). Turns out I was severely dehydrated and needed to pass some good ole material. I was kinda embarrassed about it. How many people come to the ER because they are backed up? A: It's honestly not uncommon at all. Bad constipation can be really painful and can mimic a lot of serious conditions, so it's always better to get it checked out if you're unsure. No need to be embarrassed, we see it all the time, and you're definitely not the only one! Glad you're feeling better. 27.Q: I had a severe injury a couple of months ago and was scared of going to the ER due to the costs. Is that a genuine fear? I fear that if my life is in danger, I'd be too scared to call an ambulance or go to the ER because of costs. A: Sadly, I totally get it, and I share your concerns. The cost of care in the US can be outrageous, and it's not uncommon for even healthcare workers like us to avoid the ER unless it feels absolutely unavoidable. The system needs serious change. No one should be afraid to get emergency care when their life might be on the line. 28.Q: What's the common thing you see children under 10 come in for? The most severe cases and the less severe cases? A: Most common reason kids under 10 come in? Definitely fever or upper respiratory infections — especially in the winter. We see tons of those. On the more severe end, things like allergic reactions, accidental ingestions, and trouble breathing. 29.Q: How often do patients not believe your diagnosis? Got some fun examples? A: It happens, especially with patients experiencing psychosis. Trying to convince someone that the spiders they see crawling on them aren't real can be really tough. But every now and then, someone surprises you. I once had a patient tell me there was a bug walking in their ear. At first, I assumed it was drug-related paranoia, but sure enough, there really was a bug in there. So you always stay alert and never assume. 30.Q: Whats the craziest thing someone has put in their butt? A: The wildest one I've personally seen was a huge sausage, like, way beyond what you'd think is possible. The surgeons ended up taking it out in the OR, and their official report literally just said, 'VERY large foreign body removed.' One of those cases where no one needed to say much... we all just nodded. 31.Q: Do all the staff sleep with each other like in movies, or is that, like, just in movies? A: That's mostly just in the movies, but every hospital definitely has its fair share of drama. When you work long hours in a high-stress environment, relationships and gossip happen. It's not like Grey's Anatomy, but yeah, things go on. 32.Q: Whats the worst thing you have seen someone (mostly) recover from? A: I've seen people come back from the brink of death more times than you'd think. Human resilience is incredible. One of the worst recoveries I've witnessed was a patient with alcoholic liver failure who had massive variceal bleeding. They were in the ICU for months, with complication after complication, and somehow pulled through. It's rare, but being young or just having a strong body to start with can really tip the odds. 33.Q: What is the best way to advocate for yourself if you think the doctor or nurse has it wrong? A: The best thing you can do is speak up, respectfully but clearly. Share your concerns, ask questions, and don't be afraid to say if something doesn't feel right. I've had patients or family members correct me before, and they were absolutely right. That input matters. At the same time, remember that getting to be an ER doctor takes a lot of training and experience. Most of the time, we're making decisions based on patterns we've seen over and over. But we're human too — and a good doctor will always listen. You're part of the team when it comes to care. Do you work in an ER or a similar medical setting? Tell us about your experiences in the comments or via the anonymous form below: Also in Internet Finds: Lawyers Are Sharing Their Juiciest "Can You Believe It?!" Stories From The Courtroom, And They're As Surprising As You'd Expect Also in Internet Finds: 51 People Who Quickly Discovered Why Their Hilariously Clueless Partner Was Single Before Meeting Them Also in Internet Finds: People Are Sharing "The Most Believable Conspiracy Theories," And Now I'm Questioning Everything I Thought I Knew
Medscape
2 hours ago
- Medscape
Missed Target Treatment Times May Increase MI Mortality
When it comes to delivering timely treatment for patients experiencing myocardial infarction (MI), many hospitals are continuing to fall short of national guidelines, new research showed. Benchmarks for percutaneous coronary intervention, the standard of care for acute ST-elevation MI (STEMI), aren't being met in some cases. Delays in care in the key metric of the time from first contact with medical care to angioplasty with stenting resulted in worse patient outcomes and were associated with increased in-hospital mortality risk in some cases, according to the findings, published on June 11 in JAMA Cardiology . 'There are two categories of patient delays: Those that are patient-centered and those that are system-centered,' said Neal S. Kleiman, MD, Houston Methodist DeBakey Heart and Vascular Center, Houston, the senior author of the new study. 'We don't have control over patient-related factors, but there is a lot we can do in terms of hospital systems.' For the retrospective cross-sectional study, Kleiman and his colleagues analyzed data on 73,826 patients with STEMI or STEMI equivalent from 503 sites across the United States. The goal was to determine site-level variability in patterns of treatment times and clinical outcomes from 2020 to 2022 based on an analysis of data from the American Heart Association's Get With the Guidelines — Coronary Artery Disease registry — a quality improvement program for patients with coronary artery disease, acute MI and chest pain. The authors said the study is the first large-scale analysis of treatment goals and outcomes in STEMI based on hospital performance. The researchers found an association between failure to reach the target time from first medical contact with care to angioplasty with stenting — 90 minutes or less — and increased risk for in-hospital mortality for primary presentations and transfers (adjusted odds ratio, 2.21; 95% CI, 2.02-2.42, and 2.44; 95% CI, 1.90-3.12, respectively). Low-performing hospitals were associated with increased risk for mortality and longer stays in the hospital than were high-performing hospitals. However, hospital location and case volume were not associated with worse outcomes. The guidelines recommend a target time from first contact with care to angioplasty with stenting of 90 minutes or less for patients presenting directly to hospitals offering angioplasty with stenting and 120 minutes or less for patients requiring transfer to a facility offering the procedure. The study findings revealed significant variability between hospital sites in meeting the key metric of the recommendations — adherence in at least 75% of patients with STEMI. At hospitals with the capability to perform angioplasty with stenting, the target was met in 72.2% of patients at high-performing sites, 60.8% at intermediate-performing sites, and 46.0% at low-performing sites. When patients required transfers to other facilities with the capability to perform angioplasty, a target first medical contact-to-device treatment time of 120 minutes or less was achieved in 72.3% of patients at high-performing sites, 48.8% at intermediate performing sites, and 21.9% at low-performing sites, according to the researchers. In these hospitals, treatment delays were caused primarily by longer stays in the emergency department and time from arrival in the catheterization laboratory to stenting. Limitations of the study included the fact registry responses were provided on a voluntary basis and may not reflect the totality of STEMI care in all geographical areas, according to the researchers. The analysis also lacked data on follow-up after discharge, making it difficult to extrapolate the findings over the long term, they said. Yasser M. Sammour, MD, MSc, cardiology fellow at Houston Methodist DeBakey Heart and Vascular Center, who led the work, said several decades of research have highlighted the importance of treating patients with STEMI efficiently. A previous registry study found fewer treatment delays were linked to reduced mortality. 'The current study tried to take that research one step further, assessing how factors such as hospital performance and location affect patient outcomes,' Sammour said. The result, he said: 'We're still underperforming. We need to have coordinated strategies with local intervention at the hospital level to examine where significant delays in percutaneous coronary intervention time are occurring.' The absence of uniformity in established performance measures such as time to initiate treatment in STEMI has led to calls for greater adherence to current recommendations. In an editorial accompanying the journal article, Roxana Mehran, MD, Mount Sinai Fuster Heart Hospital in New York City, wrote: 'After two decades of data collection, national initiatives, and public accountability, the next step must involve tailored solutions addressing barriers within each institution. Bridging the gap now requires renewed efforts and commitments to prioritize timely, coordinated STEMI care. Until then, the clock will continue to tick — against our patients.'
